Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Immune Cell Changes in Prostate Cancer Patients Receiving Brachytherapy

Studies immune cells in blood and tissue during prostate cancer radiation treatment.

Plain-language title generated from the registry record
Registry title: Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy

Key facts

Where
Augsburg, Erlangen, and Munich, GermanySee the 3 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer who are treated with brachytherapy (internal radiation). Some have a first treatment, others have a repeat treatment.

Age
18 years or older
Sex
Men only
Disease stage
Prostate cancer treated with brachytherapy. Arm 1 is a first treatment with I-125 seeds or HDR-BT. Arm 2 is a repeat (salvage) treatment with HDR- or PDR-BT.
Earlier treatment
Arm 1: no earlier treatment for prostate cancer. Arm 2: no radiation therapy in the three months before the repeat treatment, no prostatectomy in the past, and full records of earlier treatment.

Main reasons for not taking part

  • Auto-immune disease that was there before
  • Taking blood-thinning medication
  • Substance abuse

Read by machine on 12 November 2026.

Where in Germany

  • Klinik für StrahlentherapieAugsburg, GermanyContact: Klinik für Strahlentherapie AugsburgNot yet recruiting
  • Strahlenklinik ErlangenErlangen, GermanyContact: Strahlenklinik Erlangen AmbulanzTaking people
  • Klinik und Poliklinik für Strahlentherapie und RadioonkologieMunich, GermanyContact: Klinik und Poliklinik für Strahlentherapie und RadioonkologieNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
University of Erlangen-Nürnberg Medical School
Trial code
NCT07131956
Record updated
18 November 2025
Original description
Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.Read full original descriptionShow less

Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy (ImmunBioProBrachy)

Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.

Inclusion: Primary treatment with I-125 seeds or HDR-BT; No previous treatment for prostate cancer; Age ≥ 18 years; HDR- or PDR-BT; No radiation therapy within three months before salvage treatment; Complete documentation available on previous treatment for prostate cancer; No history of prostatectomy; Age ≥ 18 years.

Exclusion: patients under bloodthinning medication; Pre-existent auto-immune disease; substance abuse.

ClinicalTrials.gov NCT07131956